Re: Verve. It would be pretty misleading -- one might say Fibrogenic -- to tout the second generation LNP as expected to solve the problem if they saw they same liver effects preclinically. He did say that it was "well tolerated at therapeutic doses" in the 75 patients exposed in third party testing. I thought it was pretty clearly implied that Verve added the "proprietary" GALNAc targeting moetity to what was licensed -- if it's proprietary to Verve, it wouldn't be something the third party licensed, would it? Also, Kathiresan used the word "added" a couple times, which I took to mean, added to what was licensed.
Still, even though Kathiresan is touting the GALNAC as a reason he expects the second generation to solve this issue, there is always the possibility that adding it the LNP will create a problem not present in the 75 people who were tested.
I bought a few shares, it's beaten down and I have a close relative with likely FH (albeit response to moderate statin treatment), so I want to root for this to work.
News 
Market Data 
Discover 
